A clonazepam metabolite-to-parent ratio measured in muscle should not be read as though it came from blood. In a 109-case autopsy study, median 7-aminoclonazepam/clonazepam ratios were 31 in peripheral blood, nine in psoas muscle and four in lateral vastus muscle. The matrix itself materially changed the observed relationship.
What did those denominators represent?
Øiestad and colleagues included 109 benzodiazepine- or z-hypnotic-positive cases from a larger 183-case specimen project. Not every case contained clonazepam, and not every parent finding had a paired quantifiable metabolite finding.
The metabolite/parent ratio summaries used 54 paired peripheral-blood results, 37 psoas-muscle pairs and 43 lateral-vastus pairs. These are compound- and matrix-specific subsets. The study’s total of 109 must not be presented as the denominator for every ratio.
The muscle and blood measurements had different units
Peripheral-blood clonazepam had a median concentration of 0.0060 mg/L, while the psoas and lateral-vastus medians were 0.016 and 0.028 mg/kg. For 7-aminoclonazepam, the corresponding medians were 0.15 mg/L in blood and 0.13 mg/kg in each muscle.
Those concentration medians describe the reported positive findings, whose counts differed. Dividing group medians does not reproduce the median of the individual parent/metabolite pairs. Within one matrix, the metabolite/parent ratio uses matching units and is dimensionless; a muscle-to-blood comparison instead combines mg/kg with mg/L and must retain that distinction.
Table III reported median parent clonazepam muscle/blood concentration ratios of 2.1 for psoas and 4.6 for lateral vastus, compared with 0.80 and 0.78 for the metabolite. Thus, the parent was relatively enriched in muscle compared with its metabolite. A general statement that both compounds distribute identically would miss the observed pattern.
Collection and preparation shaped the comparison
Samples were collected during autopsies from June 2013 through November 2016, generally within a week of death. Peripheral blood was femoral blood expressed after iliac-vein transection and cessation of initial flow, using thigh and groin compression. It was not an unspecified cardiac specimen.
After laboratory arrival, samples were refrigerated at 4°C, typically for one to two weeks. Muscle homogenates used approximately 3.5 g tissue with 14 mL water. Results were corrected for dilution only after the homogenate result exceeded the method’s quantitation limit. That preparation could reduce detection of low muscle concentrations.
Most cases had no or slight putrefaction; four had moderate putrefaction. The investigators did not validate the same relationships in severe decomposition, burns or severely injured bodies lacking peripheral blood.
Why the ratio was not a validated ingestion clock
The authors considered both metabolism during life and possible postcollection conversion of nitrobenzodiazepines to 7-amino metabolites as explanations for higher metabolite concentrations. They lacked antemortem concentrations and could not determine which matrix best reflected the concentration at death.
The data therefore do not establish a time-since-ingestion equation. A lower muscle ratio does not independently prove more recent use than a higher blood ratio, nor does a high metabolite ratio establish that every change occurred during life. Postmortem and analytical processes remain possible influences.
What supported the reported measurements?
Screening and confirmation used distinct UHPLC–MS/MS procedures. Confirmation quantitation limits were 0.00079 mg/L for clonazepam and 0.0057 mg/L for 7-aminoclonazepam. Results below the relevant limits were omitted from evaluation. Alternative matrices used whole-blood calibration, with separate checks of recovery and matrix effects; matrix-specific calibration would have been preferred.
These limits and preparation steps belong with the results. They are not thresholds for impairment or cause of death. Interpretation should preserve the parent and metabolite identities, exact muscle, units, pair count and specimen history. For a different attribution issue, see whether clonazepam-related findings establish clonazafone exposure.
Primary source
Øiestad EL, Øiestad ÅML, Middelkoop G, Brochmann GW, Thaulow CH, Vindenes V. Comparative Study of Postmortem Concentrations of Benzodiazepines and Z-Hypnotics in Several Different Matrices. Journal of Analytical Toxicology. 2023;47:287–298. doi:10.1093/jat/bkac106.
Leave a Reply